Opinion|Videos|May 2, 2025
Weighing QoL and Toxicity in 1L EGFRm NSCLC Treatment Decisions
Panelists discuss how quality-of-life (QoL) considerations and individual toxicity profiles significantly impact first-line (1L) treatment decisions, with different regimens having distinct adverse effect profiles.
Advertisement
Episodes in this series
Quality-of-Life and Toxicity Considerations
Main Discussion Topics:
- Comparative toxicity profiles of available treatment regimens
- Impact of adverse effects on patient QoL
- Prophylactic strategies to mitigate treatment-related adverse events
Key Points for Physicians:
- Osimertinib monotherapy is extremely well tolerated with minimal impact on daily life
- FLAURA2 (chemotherapy + osimertinib) has more intensive induction followed by manageable maintenance
- Amivantamab + lazertinib has unique toxicities, including scalp rash, paronychia, hypoalbuminemia, and venous thromboembolism risk
Notable Insights:
Prophylactic strategies (COCOON for dermatologic toxicities; SKIPPirr for infusion reactions, anticoagulation) can significantly reduce adverse events with amivantamab/lazertinib.
Clinical Significance:
Selection of therapy requires careful assessment of toxicity profiles in the context of patient comorbidities, support systems, and preferences regarding appearance and lifestyle impact.
Advertisement
Related to this article
Researchers at Wake Forest University School of Medicine identified a protein that may help breast cancer spread to the brain and evade immune defenses.
Benjamin Weinberg, MD, discusses the FDA approval of daraxonrasib, RASolute 302 survival data, safety considerations, and future RAS-targeted therapies in pancreatic cancer.
Half of lenalidomide-refractory patients with 1 to 3 prior lines remained alive and progression free at least 5 years after a single cilta-cel infusion.
Andrew Kuykendall, MD, discusses the FDA approval of rusfertide and how to apply it in clinical practice for polycythemia vera management.
An NDA seeks FDA approval of savolitinib plus osimertinib for EGFR-mutated NSCLC with MET overexpression or amplification after EGFR TKI therapy.
Jason Hafron, MD, discusses the emotional, clinical, and financial burden of false positive cancer screening results and improved risk stratification.
Raajit K. Rampal, MD, PhD, discusses JAK inhibitor choice in cytopenic myelofibrosis, emerging combinations, and anemia-directed agents.
The sNDA for elinzanetant seeks FDA approval for moderate-to-severe vasomotor symptoms in women receiving endocrine therapy for HR-positive breast cancer.
Advertisement
Advertisement
Trending on OncLive
1
Ifinatamab Deruxtecan BLA Voluntarily Withdrawn in Previously Treated Extensive-Stage SCLC
2
China's NMPA Approves Pirtobrutinib Across CLL
3
FDA Grants Priority Review to Elinzanetant for Endocrine Therapy–Associated Vasomotor Symptoms in HR+ Breast Cancer
4
Long-Term PERSEUS Data Confirm Durable PFS Benefit With D-VRd in Transplant-Eligible Newly Diagnosed Myeloma
5